Proficio Capital Partners LLC purchased a new position in shares of Moderna, Inc. (NASDAQ:MRNA – Free Report) in the 2nd quarter, according to the company in its most recent filing with the SEC. The fund purchased 4,251 shares of the company’s stock, valued at approximately $298,000.
Other institutional investors and hedge funds have also modified their holdings of the company. Allied Private Wealth LLC acquired a new position in Moderna in the second quarter valued at approximately $30,000. Archer Investment Corp acquired a new stake in Moderna during the 2nd quarter worth $36,000. Canton Hathaway LLC bought a new stake in shares of Moderna during the 1st quarter valued at $31,000. Frazier Financial Advisors LLC acquired a new position in shares of Moderna in the 2nd quarter valued at $45,000. Finally, Freestone Grove Partners LP acquired a new position in shares of Moderna in the 2nd quarter valued at $46,000. 75.33% of the stock is owned by institutional investors.
Insider Transactions at Moderna
In other news, President Stephen Hoge sold 53,336 shares of Moderna stock in a transaction dated Monday, June 15th. The stock was sold at an average price of $51.37, for a total transaction of $2,739,870.32. Following the transaction, the president owned 1,483,848 shares in the company, valued at $76,225,271.76. The trade was a 3.47% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Shannon Klinger sold 3,471 shares of the business’s stock in a transaction that occurred on Tuesday, September 1st. The shares were sold at an average price of $139.95, for a total value of $485,766.45. Following the completion of the transaction, the insider owned 74,129 shares of the company’s stock, valued at $10,374,353.55. This represents a 4.47% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Company insiders own 10.80% of the company’s stock.
Moderna Price Performance
Moderna (NASDAQ:MRNA – Get Free Report) last posted its earnings results on Friday, July 31st. The company reported ($1.97) earnings per share for the quarter, topping the consensus estimate of ($2.03) by $0.06. Moderna had a negative return on equity of 28.30% and a negative net margin of 141.43%.The firm had revenue of $145.00 million for the quarter, compared to analyst estimates of $102.93 million. During the same period in the previous year, the company posted ($2.13) earnings per share. The company’s revenue for the quarter was up 2.1% on a year-over-year basis. On average, research analysts expect that Moderna, Inc. will post -6.09 EPS for the current year.
Trending Headlines about Moderna
Here are the key news stories impacting Moderna this week:
- Positive Sentiment: Moderna and Merck reported that the Phase 3 INTerpath-001 trial of intismeran autogene plus Keytruda met its primary recurrence-free-survival endpoint in resected stage IIB–IV melanoma. It was the first positive Phase 3 result for an mRNA-based cancer therapy and strengthens Moderna’s long-term oncology outlook, although detailed data have not yet been released. Moderna melanoma trial article
- Positive Sentiment: Technical analysts describe the recent consolidation as a potential bullish pennant following the cancer-vaccine-driven breakout. Elevated short interest could provide additional buying pressure if the shares break above resistance. Moderna technical forecast
- Neutral Sentiment: Chief Legal Officer Shannon Klinger sold 3,471 shares for approximately $486,000 under a pre-arranged Rule 10b5-1 plan to cover tax withholding tied to vested equity awards. Because the transaction was planned and tax-related, it provides limited insight into management’s view of Moderna’s valuation.
- Negative Sentiment: Rothschild & Co. Redburn downgraded Moderna from Neutral to Sell, saying the cancer-vaccine rally has made the stock overvalued. The firm raised its price target to $81 from $40, but the new target remains well below recent trading levels, intensifying profit-taking concerns. Rothschild Moderna downgrade
- Negative Sentiment: GSK is advancing an mRNA influenza vaccine toward Phase 3 after reporting stronger immune responses in Phase 2. The competing program could challenge Moderna’s newly approved mFlusiva and increase pressure on its commercial vaccine pipeline. GSK mRNA flu vaccine competition
Analyst Upgrades and Downgrades
A number of equities research analysts recently commented on the company. CLSA raised Moderna to an “outperform” rating in a research note on Friday, August 28th. Piper Sandler restated an “overweight” rating on shares of Moderna in a report on Monday, August 3rd. Brookline Capital Markets restated a “buy” rating on shares of Moderna in a research report on Wednesday, August 19th. Morgan Stanley upped their price target on Moderna from $39.00 to $89.00 and gave the company an “equal weight” rating in a research note on Thursday, August 20th. Finally, JPMorgan Chase & Co. increased their price target on shares of Moderna from $40.00 to $77.00 and gave the company an “underweight” rating in a research report on Friday, August 21st. Seven investment analysts have rated the stock with a Buy rating, twelve have assigned a Hold rating and five have issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Moderna has a consensus rating of “Hold” and an average target price of $76.72.
Read Our Latest Analysis on MRNA
Moderna Company Profile
Moderna, Inc is a biotechnology company headquartered in Cambridge, Massachusetts, specializing in messenger RNA (mRNA) therapeutics and vaccines. The company’s platform leverages synthetic mRNA to instruct cells to produce proteins that can prevent or treat diseases. Since its founding in 2010, Moderna has advanced from early-stage research into a broad pipeline of vaccine and therapeutic candidates designed to address infectious diseases, rare genetic disorders and chronic illnesses.
Moderna’s flagship product is its mRNA-based COVID-19 vaccine, which was the first of its kind to receive emergency use authorization and later full approval in multiple jurisdictions.
Featured Articles
- Five stocks we like better than Moderna
- Revolution Medicines Got Its Breakthrough—What Moves It Next?
- Retail Earnings Just Exposed a Bigger Divide in the U.S. Consumer Economy
- FB Financial’s Southern Expansion and Buybacks Drive Analyst Optimism
- AST SpaceMobile Stock Soared 12%—This Was the Catalyst
Want to see what other hedge funds are holding MRNA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Moderna, Inc. (NASDAQ:MRNA – Free Report).
Receive News & Ratings for Moderna Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Moderna and related companies with MarketBeat.com's FREE daily email newsletter.
